Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
3.
Eur J Dermatol ; 32(5): 629-631, 2022 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-36468733

RESUMEN

Background: The guidelines for the treatment of chronic spontaneous urticaria (CSU) recommend adding omalizumab to the treatment of patients with uncontrolled disease despite four-fold doses of second-generation antihistamines (AH). On the contrary, some studies revealed that omalizumab was effective without concomitant AH and several authors suggest tapering off AH when CSU is controlled with omalizumab. Objectives: The aim of our study was to evaluate the use of AH during treatment with omalizumab in patients with CSU in real clinical practice. Materials & Methods: This was a multicentre cross-sectional and observational study conducted by the Catalan and Balearic Chronic Urticaria Network (XUrCB) based on a cohort of 298 CSU patients treated with omalizumab. Results: In total, 23.5% of our patients decided themselves to stop taking AH during omalizumab treatment. The ratio of patients with CSU without concomitant inducible urticaria and the percentage of patients with a good response to omalizumab (UAS7≤6 and/or UCT ≥12) were higher in those who stopped taking AH. Conclusion: More studies are required to identify the phenotypic characteristics of patients responding to omalizumab as monotherapy in order to avoid overtreating with AH. Our study suggests that patients with CSU without concomitant inducible urticaria and those who achieve a good response to omalizumab tend to be controlled by omalizumab without AH. In order to establish guidelines on how to stop AH, further evidenced-based studies are required.


Asunto(s)
Urticaria Crónica , Urticaria , Humanos , Urticaria Crónica/tratamiento farmacológico , Omalizumab/uso terapéutico , Estudios Transversales , Antagonistas de los Receptores Histamínicos/uso terapéutico , Urticaria/tratamiento farmacológico
4.
Skinmed ; 17(5): 298-304, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31782702

RESUMEN

Standards in post-surgery wound care management require a rapid healing process in order to prevent and minimize abnormal scarring. For the healing process to start as early as possible, the ideal dressing should be applied directly on the open wound and perfectly adapt to it. The authors report a case study series regarding the efficacy of a flexible film-forming wound dressing in the form of a gel (Stratamed®, Stratpharma AG, Switzerland) that is approved for the use on open wounds and injured skin. Evidence from the current study shows that, while remaining safe to use, the dressing was efficacious in promoting epithelialization and accelerated wound healing of areas in which skin integrity had been compromised, and at the same time prevented the formation of abnormal scars. Results were observed across a broad range of dermatologic surgical procedures. All treated conditions showed a beneficial outcome, as well as an overall favorable patient treatment perception.


Asunto(s)
Neoplasias Faciales/cirugía , Apósitos Oclusivos , Geles de Silicona/uso terapéutico , Neoplasias Cutáneas/cirugía , Herida Quirúrgica/terapia , Anciano , Anciano de 80 o más Años , Quemaduras/terapia , Cicatriz/prevención & control , Erupciones por Medicamentos/terapia , Femenino , Humanos , Masculino , Apósitos Oclusivos/efectos adversos , Repitelización , Geles de Silicona/efectos adversos , Herida Quirúrgica/complicaciones
5.
J Am Acad Dermatol ; 58(4): 685-90, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18342717

RESUMEN

BACKGROUND: Infantile hemangiomas have a characteristic natural history of rapid proliferation in the first weeks of life followed by spontaneous involution. At birth, they may be present as a precursor lesion. Sometimes one may see precursor lesions that never undergo a growth phase or that undergo minimal growth. It is unclear the exact nature of these precursor-like lesions. OBJECTIVE: We sought to describe the morphology and histopathology of these precursor-like lesions. METHODS: We describe 4 patients with macules resembling precursor lesions of hemangiomas that did not show proliferation phase or minimal growth. The histopathologic and immunohistochemical study with glucose transporter-1 was performed in all of these cases. RESULTS: The skin biopsy specimen showed superficial ectatic vessels that reacted with anti-glucose transporter-1 antibodies. All skin biopsy specimens exhibited capillary lobules in papillary dermis and, in two of them, in the reticular dermis and subcutis. LIMITATIONS: This text is limited by the number of cases reported. CONCLUSIONS: Precursor lesions of hemangioma that do not show proliferation phase or minimal growth represent, in the view of glucose transporter-1 immunoreactivity, true hemangiomas of infancy with an aborted or arrested growth cycle.


Asunto(s)
Hemangioma/patología , Preescolar , Femenino , Transportador de Glucosa de Tipo 1/inmunología , Humanos , Lactante , Telangiectasia/patología
6.
Eur J Dermatol ; 18(6): 693-9, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18955203

RESUMEN

Psoriasis is a common immune-mediated disease that affects approximately 2% of the world's population. Most patients require lifelong treatment and many of the current systemic therapies are complicated by significant toxicities or inconvenience when administered long-term. New biological psoriasis therapies have been developed, which are thought to act through targeted molecular pathways, so as to administer them continuously without causing any relevant toxicity. Nevertheless, acute and chronic dermatological adverse effects are frequently observed, but knowledge about them is limited and the potential pathogenic mechanisms have not yet been identified. We present 7 patients from our dermatological department who presented different cutaneous adverse effects (2 erythrodermias, 1 palmoplantar pustulosis, 1 flexural psoriasis, 1 eczema, 1 neutrophilic dermatosis and 1 papular eruption) during treatment with biological drugs (4 patients with efaluzimab, 2 patients with infliximab and 1 patient with etanercept). The use of biological agents is expanding worldwide as new alternative treatments for psoriasis and other chronic inflammatory diseases. The increased use of these treatments has allowed identification of their acute and chronic systemic adverse events. Nevertheless, the dermatological adverse events of these biological drugs are less well known due to few reports about them and lack of information about their pathogenic mechanisms. Exact diagnosis of these cutaneous eruptions is very important in order to decide the need for discontinuation of the biological treatment.


Asunto(s)
Anticuerpos Monoclonales/efectos adversos , Erupciones por Medicamentos/etiología , Inmunosupresores/efectos adversos , Psoriasis/tratamiento farmacológico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Adulto , Anticuerpos Monoclonales Humanizados , Erupciones por Medicamentos/patología , Etanercept , Femenino , Humanos , Inmunoglobulina G/efectos adversos , Infliximab , Masculino , Persona de Mediana Edad , Receptores del Factor de Necrosis Tumoral
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA